| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CAMBRIDGE, Mass.—In a deal potentially worth some$200 million to BIND Therapeutics and marking its third major deal with BigPharma since the start of 2013, BIND announced April 22 that it has enteredinto a strategic collaboration with London-based AstraZeneca. Through thiscollaboration, the two companies plan to develop and commercialize an Accurin—atargeted and programmable cancer nanomedicine from BIND's MedicinalNanoengineering platform—based on a molecularly targeted kinase inhibitordeveloped and owned by AstraZeneca.
 
 
Under the terms of the agreement, the companieswill work together to complete Investigational New Drug-enabling studies ofthe lead Accurin identified from a previously-completed feasibility program.AstraZeneca will then have the exclusive right to lead development andcommercialization, while BIND will lead manufacturing during the developmentphase.
 
 
BIND could receive upfront and pre-approvalmilestone payments totaling $69 million, plus more than $130 million inregulatory and sales milestones and other payments—not to mention tieredsingle- to double-digit royalties on future sales.
 
 
Added to BIND's January deal with Amgen and Marchdeal with Pfizer, a company spokesperson notes that this is the third globalpartnership in four months with Big Pharma seeking access to BIND'snanomedicine technology to develop highly selective and targeted drugs, and"marks nearly $1 billion in total deal value to BIND and a 'tipping point' fornanomedicines."
 
 
"One year ago, BIND started several feasibilityprojects with major pharmaceutical companies," noted Scott Minick, presidentand CEO of BIND. "Our collaboration with AstraZeneca is the first one completedand had very successful results. Due to the advanced nature of this program, wenow plan to move an Accurin with optimized therapeutic properties quickly intoproduct development."
 
 
This collaboration and the others, BIND has noted,is based on emerging data suggesting that nanomedicines such as Accurins"selectively accumulate in diseased tissues and cells, leading to higher drugconcentrations at the site of the tumor and reduced exposure to healthytissues."
 
 
In addition to developing Accurins incollaboration with pharmaceutical and biotechnology partners, BIND isdeveloping a pipeline of novel Accurins that it believes hold "extraordinarypotential" to become best-in-class drugs and improve patient outcomes in theareas of oncology, inflammatory diseases and cardiovascular disorders. BIND'slead product candidate, BIND-014, is currently entering Phase II clinicaltesting in cancer patients and is designed to selectively target PSMA, asurface protein upregulated in a broad range of solid tumors.
 
 
"AstraZeneca believes that targeted therapieswhich specifically address the underlying mechanisms of disease are the futureof personalized cancer treatment," said Susan Galbraith, head of AstraZeneca'sOncology Innovative Medicines Unit. "Our oncology teams are actively exploringa range of platforms to deliver targeted therapies, with a strategic focus onunlocking the significant potential of nanoparticles as an approach to cancertreatment. We view BIND's targeted nanomedicines as a leading technology inthis field."


About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue